Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United KingdomIPO:
28 September 2017Website:
http://www.nucana.comNext earnings report:
16 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:21:10 GMTDividend
Analysts recommendations
Institutional Ownership
NCNA Latest News
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Global Healthcare Conference.
NuCana (NASDAQ: NCNA ) stock is rising on Wednesday as the clinical-stage biopharmaceutical company's shares experience heavy trading this morning. That has more than 9.6 million shares of the company's stock changing hands as of this writing.
NCNA is a beaten-down stock for numerous reasons, including failure of its prior lead candidate (Acelarin) in two phase 3 trials, as well as a limited cash runway. However, there are good reasons to believe that NCNA's current lead candidate, NUC-3373, will be successful. NUC-3373 aims to replace 5-fluorouracil (5FU) by overcoming its numerous limitations. Notably, 5FU is still used in a variety of malignancies. Importantly, 5FU-based chemotherapy regimens remain the cornerstone for treatment of colorectal cancer.
NuCana (NASDAQ: NCNA ) stock is sliding lower on Tuesday as the clinical-stage biopharmaceutical company prepares for a presentation this week. NuCana is set to attend the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 in Boston, Mass.
NuCana PLC Sponsored ADR (NCNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
NuCana (NASDAQ: NCNA ) stock is sliding lower on Monday after the company got an unfortunate update from the Technical Board of Appeal (TBA) of the European Patent Office (EPO). The bad news for investors in NCNA stock is the TBA has determined that the company's European Patent 2955190 isn't valid.
What type of business is NuCana?
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients with recurrent ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary tract cancer; Phase II clinical trial for the treatment of patients with platinum-resistant ovarian cancer; and Phase III clinical trial for the treatment of patients with pancreatic cancer. The company is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors and in a Phase 1b/2 clinical trial for patients with advanced colorectal cancer; and NUC-7738, a nucleoside analog that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological tumors. It has a research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides; and an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.
What sector is NuCana in?
NuCana is in the Healthcare sector
What industry is NuCana in?
NuCana is in the Biotechnology industry
What country is NuCana from?
NuCana is headquartered in United Kingdom
When did NuCana go public?
NuCana initial public offering (IPO) was on 28 September 2017
What is NuCana website?
https://www.nucana.com
Is NuCana in the S&P 500?
No, NuCana is not included in the S&P 500 index
Is NuCana in the NASDAQ 100?
No, NuCana is not included in the NASDAQ 100 index
Is NuCana in the Dow Jones?
No, NuCana is not included in the Dow Jones index
When does NuCana report earnings?
The next expected earnings date for NuCana is 16 August 2024